Toxic and drug-induced peripheral neuropathies: updates on causes, mechanisms and management.

Details

Ressource 1Download: BIB_297454487D9A.P001.pdf (288.26 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_297454487D9A
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Toxic and drug-induced peripheral neuropathies: updates on causes, mechanisms and management.
Journal
Current Opinion in Neurology
Author(s)
Diezi M., Buclin T., Kuntzer T.
ISSN
1473-6551 (Electronic)
ISSN-L
1350-7540
Publication state
Published
Issued date
2013
Peer-reviewed
Oui
Volume
26
Number
5
Pages
481-488
Language
english
Notes
Publication types: Journal ArticlePublication Status: ppublishDocument Type: Review
Abstract
PURPOSE OF REVIEW: This review discusses publications highlighting current research on toxic, chemotherapy-induced peripheral neuropathies (CIPNs), and drug-induced peripheral neuropathies (DIPNs).
RECENT FINDINGS: The emphasis in clinical studies is on the early detection and grading of peripheral neuropathies, whereas recent studies in animal models have given insights into molecular mechanisms, with the discovery of novel neuronal, axonal, and Schwann cell targets. Some substances trigger inflammatory changes in the peripheral nerves. Pharmacogenetic techniques are underway to identify genes that may help to predict individuals at higher risk of developing DIPNs. Several papers have been published on chemoprotectants; however, to date, this approach has not been shown effective in clinical trials.
SUMMARY: Both length and nonlength-dependent neuropathies are encountered, including small-fiber involvement. The introduction of new diagnostic techniques, such as excitability studies, skin laser Doppler flowmetry, and pharmacogenetics, holds promise for early detection and to elucidate underlying mechanisms. New approaches to improve functions and quality of life in CIPN patients are discussed. Apart from developing less neurotoxic anticancer therapies, there is still hope to identify chemoprotective agents (erythropoietin and substances involved in the endocannabinoid system are promising) able to prevent or correct painful CIPNs.
Pubmed
Web of science
Create date
07/12/2013 16:56
Last modification date
20/08/2019 13:09
Usage data